Metabolic Syndrome May Up Risk for VTE Recurrence After DVT
Significantly higher odds seen for all four components of MetS, with largest risk increase for hyperlipidemia
Deep Vein Thrombosis
Rivaroxaban May Be the Best Strategy for Deep Vein Thrombosis Prevention in Total Knee Replacement
A review and meta-analysis of 25 randomized controlled trials showed that single-agent treatment strategies were generally more effective than combination strategies.
Extended Oral Anticoagulation Therapy for First Unprovoked Deep Vein Thrombosis
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
Risk Factors for Recurrent Venous Thromboembolism in Patients With Sickle Cell Disease
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Using Neural Networks to Assess Risk for Deep Vein Thrombosis
The neural network developed in this study yielded a false-negative rate of 0.22%.
No Association Found Between Locations of Venous Thromboembolism and Occult Cancer
An analysis of 2300 patients found similar prevalence of abdominal, pelvic, and thoracic cancer in patients with deep vein thrombosis and pulmonary embolism.
Lack of Thromboprophylactic Benefit With Rivaroxaban in Ambulatory Patients With Cancer
Patients receiving rivaroxaban did not experience a statistically significant decrease in thrombotic events compared with patients receiving placebo.
Thromboprophylaxis May Not Benefit Patients With Advanced Cancer in Palliative Care
Thromboprophylactic treatment and serum albumin levels were not found to be associated with deep vein thrombosis incidence.
Upper Extremity Deep Vein Thrombosis May Be Linked to Post-Thrombotic Syndrome
Researchers conducted a systematic literature review to characterize the complications experienced by patients with upper extremity deep vein thrombosis.
Anticoagulant Therapies in Patients With Iliofemoral Deep Vein Thrombosis
No differences were observed in patency rates or incidence of post-thrombotic syndrome in patients treated with rivaroxaban or a vitamin K antagonist.
- Loading...
Loading...
Next post in Thrombotic Disorders
Loading... 
Loading...